News & Updates
Stay up to date with the latest VAXgpo announcements, partnerships, industry insights, and important updates for our members.
News & Updates
ACIP Recommends Use of Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season
The Advisory Committee on Immunization Practices (ACIP) has recommended Merck's ENFLONSIA™ for RSV prevention in infants.
The Advisory Committee on Immunization Practices (ACIP) to the CDC has voted to recommend the use of ENFLONSIA™ (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in infants younger than 8 months of age who are born during or entering their first RSV season. This recommendation represents a significant advancement in protecting vulnerable infants from RSV disease.
Need Additional Support?
Can't find what you're looking for? Our team is here to help with any questions or additional resources you may need.